A 2-Part, Phase 1 study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics effects of DS-3801 on gastrointestinal motility in healthy subjects

Trial Profile

A 2-Part, Phase 1 study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics effects of DS-3801 on gastrointestinal motility in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2017

At a glance

  • Drugs DS-3801 (Primary)
  • Indications Constipation; Gastrointestinal motility disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 23 May 2017 New trial record
    • 02 May 2017 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top